50242-933-01 : NDC 2026 Code

50242-933-01 : Atezolizumab And Hyaluronidase-tqjs ( Tecentriq Hybreza )

Additionally :

You can get information about “50242-933-01” NDC code in 50242-933-01 in HTML format

HTML | 50242-933-01 in TXT (Plain Text) format

TXT | 50242-933-01 in PDF (Portable Document Format)

PDF | 50242-933-01 in XML format

XML formats.

NDC Code : 50242-933-01 – JSON Data Format

                
{
  "NDC": {
    "NDCCode": "50242-933-01",
    "PackageDescription": "1 VIAL, SINGLE-DOSE in 1 BOX (50242-933-01)  / 15 mL in 1 VIAL, SINGLE-DOSE",
    "NDC11Code": "50242-0933-01",
    "ProductNDC": "50242-933",
    "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
    "ProprietaryName": "Tecentriq Hybreza",
    "ProprietaryNameSuffix": null,
    "NonProprietaryName": "Atezolizumab And Hyaluronidase-tqjs",
    "DosageFormName": "INJECTION",
    "RouteName": "SUBCUTANEOUS",
    "StartMarketingDate": "20240912",
    "EndMarketingDate": null,
    "MarketingCategoryName": "BLA",
    "ApplicationNumber": "BLA761347",
    "LabelerName": "Genentech, Inc.",
    "SubstanceName": "ATEZOLIZUMAB; HYALURONIDASE (HUMAN RECOMBINANT)",
    "StrengthNumber": "1875; 30000",
    "StrengthUnit": "mg/15mL; U/15mL",
    "Pharm_Classes": "Antibodies [CS], Antibodies, Monoclonal [CS], Antibodies, Monoclonal, Humanized [CS], Endoglycosidase [EPC], Glycoside Hydrolases [CS], Programmed Death Receptor-1 Blocking Antibody [EPC], Programmed Death Receptor-1-directed Antibody Interactions [MoA]",
    "DEASchedule": null,
    "Status": "Active",
    "LastUpdate": "2025-12-16",
    "PackageNdcExcludeFlag": "N",
    "ProductNdcExcludeFlag": "N",
    "ListingRecordCertifiedThrough": "20261231",
    "StartMarketingDatePackage": "20240912",
    "EndMarketingDatePackage": null,
    "SamplePackage": "N"
  }
}